uniQure (NASDAQ:QURE) Given New $76.00 Price Target at Chardan Capital

Key Points

• Chardan Capital has raised its price target for uniQure (NASDAQ:QURE) from $35.00 to $76.00, indicating a potential upside of 60% from its current price and maintaining a "buy" rating.
• uniQure has reported strong financial performance, with Q2 earnings exceeding expectations, showing a revenue of $5.26 million against an anticipated $5.00 million.
• There has been significant institutional interest, with hedge funds increasing their positions in the stock, reflecting a growing confidence among investors in the company's prospects.

uniQure (NASDAQ:QURE - Get Free Report) had its target price raised by equities research analysts at Chardan Capital from $35.00 to $76.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. Chardan Capital's price objective suggests a potential upside of 60.00% from the stock's current price.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Wednesday. Royal Bank Of Canada reissued an "outperform" rating on shares of uniQure in a research report on Wednesday. Leerink Partners lifted their price target on shares of uniQure from $48.00 to $68.00 and gave the stock an "outperform" rating in a report on Wednesday. Cantor Fitzgerald set a $47.00 price target on shares of uniQure in a report on Wednesday, July 30th. Finally, Mizuho raised shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target on the stock in a report on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, uniQure has a consensus rating of "Buy" and an average price target of $46.36.

uniQure Price Performance

QURE stock opened at $47.50 on Thursday. The company has a market capitalization of $2.61 billion, a P/E ratio of -12.12 and a beta of 0.14. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure has a 52-week low of $4.45 and a 52-week high of $51.21. The business has a 50-day simple moving average of $15.90 and a two-hundred day simple moving average of $14.32.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. Research analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its position in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares in the last quarter. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure during the 1st quarter valued at $106,000. KLP Kapitalforvaltning AS purchased a new position in shares of uniQure during the 2nd quarter valued at $117,000. Teacher Retirement System of Texas purchased a new position in shares of uniQure during the 2nd quarter valued at $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in uniQure in the first quarter worth $152,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.